Shrinking the prostate without surgery can provide long-term relief to men with this common condition that causes annoying symptoms, such as frequent trips to the bathroom, suggests a study of nearly 500 men. According to research being presented at the Society of Interventional Radiology s 39th Annual Scientific Meeting, 72 percent of men experienced symptom improvement three years after having a new, minimally invasive, image-guided treatment performed by interventional radiologists called prostate artery embolization (PAE).
Imaging of the coronary arteries with computed tomography (CT) angiography provides an accurate assessment of arterial plaque and could have a dramatic impact on the management of diabetic patients who face a high risk of heart attacks and other cardiovascular events, according to a new multicenter study published online in the journal Radiology.
In a report of their proof of principle study in the Journal of Urology, researchers from the University of Tampere describe how the "eNose" successfully differentiated between prostate cancer and benign prostatic hyperplasia (BPH) by analyzing the "smell print" of the headspace of a urine sample (the air immediately above the urine).
Patients with peripheral arterial disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the In.Pact Admiral drug-coated balloon (Medtronic) than with standard balloon angioplasty, according to a landmark clinical study reported for the first time at the Charing Cross Symposium (5–8 April, London, UK)
TriReme Medical announced in a company release that the first three patients were enrolled in a clinical study of its unique drug-coated Chocolate percutaneous transluminal angioplasty balloon. Andrew Holden, co-principal investigator of the study, performed these procedures at Auckland City Hospital, in Auckland, New Zealand.
Metactive Medical presented new nonclinical data on one of its investigational devices at the Society of Interventional Radiology’s (SIR) Annual Scientific Meeting. The presentation focused on the company’s device that addresses the cerebral aneurysm market
A study, published in the Journal of Vascular and Interventional Radiology, highlights the benefits of the transradial approach to treat uterine fibroids and investigators find that this technique could be a “game changer” for image-guided minimally invasive treatments.
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling.
Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer.
The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA)
March 29, 2014—AccessClosure Inc. (Santa Clara, CA) announced the commercial launch of its Mynx Ace vascular closure device at ACC.14: the 63rd annual scientific session of the American College of Cardiology being held March 29–31, in Washington, DC.
March 30, 2014—Medtronic, Inc. (Minneapolis, MN) announced to the presentation of an analysis of 6-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry. The data were presented during a late-breaking clinical trial session at ACC.14, the 63rd scientific sessions of the American College of Cardiology (ACC) in Washington, DC.
March 29, 2014—Medtronic, Inc. (Minneapolis, MN) announced that the full results of the SYMPLICITY HTN-3 clinical trial were presented in a late-breaking session at the ACC.14: 63rd annual scientific sessions of the American College of Cardiology and published simultaneously online ahead of print in The New England Journal of Medicine. SYMPLICITY HTN-3 is a blinded, randomized, sham-controlled study of renal denervation for treatment-resistant hypertension. ACC.14 is being held on March 29–31, in Washington, DC.
March 24, 2014—The Society of Interventional Radiology (SIR) announced findings from a study demonstrating that 72% of men with benign prostatic hyperplasia who were treated via prostate artery embolization (PAE) continued to show symptom improvement at 3-year follow-up. Minimally invasive, image-guided PAE is a transcatheter procedure that releases microscopic beads into the artery where they lodge and temporarily block blood flow to the prostate, causing it to shrink. The study was presented at SIR’s 39th Annual Scientific Meeting in San Diego, California, and is available online as Abstract 108 at www.sirmeeting.org.
March 24, 2014—The Society of Interventional Radiology (SIR) announced that yttrium-90 (Y-90) radioembolization of the artery that supplies the liver shows promise in treating breast cancer that has spread to the liver when no other treatment options remain. In this procedure, microbeads are administered into the blood stream, float out to the smaller vessels that feed the tumor, and emit cancer-killing radiation from inside the tumor. Because Y-90 is targeted directly to the tumor, radiation damage to healthy surrounding tissues is minimized. The study was presented at the SIR’s 39th annual scientific meeting in San Diego, California, and is available as Abstract 192 at www.sirmeeting.org.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos